A61K31/425

Methods for treating ischemic heart disease by targeting TRPV4

Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.

Methods for treating ischemic heart disease by targeting TRPV4

Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.

CYANOPYRROLIDINES AS USP30 INHIBITORS AND FIBROSIS TREATMENT

The present invention relates to novel treatments of fibrotic diseases, including, inter alia, fibrosis of the lung, liver and kidney, and to substituted-cyanopyrrolidines of formula (I) having activity as inhibitors of ubiquitin specific peptidase 30 (USP30), and compositions containing said inhibitors, for use in said treatments (I).

##STR00001##

Crystal form of ozanimod hydrochloride and processes for preparation therefor

The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. ##STR00001##

Crystal form of ozanimod hydrochloride and processes for preparation therefor

The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. ##STR00001##

Bicyclic heteroaryl derivatives and preparation and uses thereof
10882832 · 2021-01-05 · ·

The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans. ##STR00001##

Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect

The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect

The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.